Douglas Stewart

National Institutes of Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

It is estimated that 10% of individuals with a myeloid malignancy carry a germline susceptibility. Using the genome-first approach, in which individuals were ascertained on genotype alone, rather than clinical phenotype, we quantified the prevalence and penetrance of pathogenic germline variants in eight myeloid malignancy predisposition (gMMP) genes. ANKRD26 , CEBPA, DDX41, MECOM, SRP72, ETV6, RUNX1 and GATA2 , were analyzed from the Geisinger MyCode DiscovEHR ( n = 170,503) and the United Kingdom Biobank (UKBB, n = 469,595). We identified a high risk of myeloid malignancies (MM) (odds ratio[OR] all genes: DiscovEHR, 4.6 [95% confidential interval (CI) 2.1–9.7], p < 0.0001; UKBB, 6.0 [95% CI 4.3–8.2], p = 3.1 × 10 -27 ), and decreased overall survival (hazard ratio [HR] DiscovEHR, 1.8 [95% CI 1.3–2.6], p = 0.00049; UKBB, 1.4 [95% CI 1.2–1.8], p = 8.4 × 10 -5 ) amongst heterozygotes. Pathogenic DDX41 variants were the most commonly identified, and in UKBB showed a significantly increased risk of MM (OR 5.7 [95% CI 3.9–8.3], p = 6.0 × 10 -20 ) and increased all-cause mortality (HR 1.35 [95% CI 1.1–1.7], p = 0.0063). Through a genome-first approach, this study genetically ascertained individuals with a gMMP and determined their MM risk and survival.

Year:

2025

Background: Congenital anomalies are associated with an increased risk of childhood cancer. However, there is a knowledge gap about health outcomes for childhood cancer survivors with congenital anomalies. Methods: We included childhood cancer survivors from the Childhood Cancer Survivor Study (n = 22,247), comparing survivors with and without self-reported anomalies. Using Cox regression, we estimated HR and 95% confidence intervals (CI) of chronic health conditions (CHC) classified per the Common Terminology Criteria for Adverse Events from 1 (mild) to 5 (fatal) and subsequent malignant neoplasms (SMN), comparing survivors by anomaly status. We calculated age-, sex-, and calendar year–specific mortality rates and standardized mortality ratios for survivors compared with the US population. Results: Among survivors, 16.9% (n = 3,880) reported a congenital anomaly. Survivors with anomalies had a higher rate of any CHC (grades 1–5: HR, 1.24; 95% CI, 1.18–1.31), severe CHCs (grades 3–5: HR, 1.29; 95% CI, 1.19–1.40), and multiple CHCs of any grade (≥2 CHCs: HR, 1.31; 95% CI, 1.24–1.39; ≥3 CHCs: HR, 1.42; 95% CI, 1.33–1.52). Survivors with anomalies had an increased rate of soft-tissue sarcomas (HR, 1.96; 95% CI, 1.12–3.44). For deaths related to the original cancer diagnosis, survivors with anomalies (compared with those with no anomalies) had a lower mortality rate (0.64 vs. 0.90 per 1,000 person-years). Conclusions: We identified an increased rate of CHCs and SMNs among childhood cancer survivors with anomalies and lower mortality directly related to the cancer diagnosis. Impact: Future work will focus on the evaluation of genetic pathways that increase the risk of CHCs and SMNs.

Year:

2025

The Radiation Effects Research Foundation (RERF) conducts research on the health effects of atomic bomb (A-bomb) radiation, supported by the long-term cooperation of survivors and their children. In response to concerns from A-bomb survivors, their offspring, and the global community, RERF has investigated transgenerational radiation effects for many years. Currently, RERF is planning the Trio Genome Study (TGS), which will utilize advanced genome sequencing to examine potential genetic effects on the offspring of survivors. This study could yield significant findings but also presents ethical challenges, particularly in ensuring that results are returned responsibly to the community. RERF first held an international workshop to address ethical, legal, and social issues related to genomic analysis in 2020, followed by formation of stakeholder committees to align the study with community perspectives. Most recently, in December 2024, an international symposium further explored frameworks important to the TGS, including risk communication, benefit-sharing, community involvement, and return of secondary findings. In genomic analysis, secondary findings comprise a deliberate search for pathogenic variants in an established list of genes in disorders associated with life-threatening manifestations. Returning these secondary findings to research participants is crucial from the perspective of benefit-sharing. Discussions emphasized the need for transparency in the return of secondary findings, especially those with actionable health implications, including sharing the rationale behind providing information about genetic variants to research participants. These frameworks will guide not only future RERF studies but also genomic research worldwide, ensuring that the findings benefit participants and communities.

Year:

2025

Year:

2025

Background: Congenital anomalies are associated with an increased risk of childhood cancer. However, there is a knowledge gap about health outcomes for childhood cancer survivors with congenital anomalies. Methods: We included childhood cancer survivors from the Childhood Cancer Survivor Study ( n = 22,247), comparing survivors with and without self-reported anomalies. Using Cox regression, we estimated HR and 95% confidence intervals (CI) of chronic health conditions (CHC) classified per the Common Terminology Criteria for Adverse Events from 1 (mild) to 5 (fatal) and subsequent malignant neoplasms (SMN), comparing survivors by anomaly status. We calculated age-, sex-, and calendar year–specific mortality rates and standardized mortality ratios for survivors compared with the US population. Results: Among survivors, 16.9% ( n = 3,880) reported a congenital anomaly. Survivors with anomalies had a higher rate of any CHC (grades 1–5: HR, 1.24; 95% CI, 1.18–1.31), severe CHCs (grades 3–5: HR, 1.29; 95% CI, 1.19–1.40), and multiple CHCs of any grade (≥2 CHCs: HR, 1.31; 95% CI, 1.24–1.39; ≥3 CHCs: HR, 1.42; 95% CI, 1.33–1.52). Survivors with anomalies had an increased rate of soft-tissue sarcomas (HR, 1.96; 95% CI, 1.12–3.44). For deaths related to the original cancer diagnosis, survivors with anomalies (compared with those with no anomalies) had a lower mortality rate (0.64 vs. 0.90 per 1,000 person-years). Conclusions: We identified an increased rate of CHCs and SMNs among childhood cancer survivors with anomalies and lower mortality directly related to the cancer diagnosis. Impact: Future work will focus on the evaluation of genetic pathways that increase the risk of CHCs and SMNs.

Year:

2025

Purpose: DROSHA , DGCR8 , and DICER1 regulate miRNA biogenesis and are commonly mutated in cancer. Although DGCR8 and DICER1 germline pathogenic variants (GPV) cause autosomal dominant tumor predisposition, no association between DROSHA GPVs and clinical phenotypes has been reported. Experimental Design: After obtaining informed consent, sequencing was performed on germline and tumor samples from all patients. The occurrence of germline DROSHA GPVs was investigated in large pediatric and adult cancer datasets. The population prevalence of DROSHA GPVs was investigated in the UK Biobank and Geisinger DiscovEHR cohorts. Results: We describe nine children from eight families with heterozygous DROSHA GPVs and a diagnosis of pineoblastoma ( n = 8) or Wilms tumor ( n = 1). A somatic second hit in DROSHA was detected in all eight tumors analyzed. All pineoblastoma tumors analyzed were classified as miRNA processing–altered 1 subtype. We estimate the population prevalence of germline DROSHA loss-of-function variants to be 1:3,875 to 1:4,843 but find no evidence for increased adult cancer risk. Conclusions: This is the first report of DROSHA- related tumor predisposition. As pineoblastoma and Wilms tumor are also associated with DICER1 GPVs, our results suggest that the tissues of origin for these tumors are uniquely tolerant of general miRNA loss. The miRNA processing–altered 1 pineoblastoma subtype is associated with older age of diagnosis and better outcomes than other subtypes, suggesting DROSHA GPV status may have important clinical and prognostic significance. We suggest that genetic testing for DROSHA GPVs be considered for patients with pineoblastoma, Wilms tumor, or other DICER1 -/ DGCR8 -related conditions and propose surveillance recommendations through research studies for individuals with DROSHA GPVs.

Year:

2025

Neurofibromatosis type 1 (NF1) is an autosomal dominant condition in which patients are heterozygous for a disruptive pathogenic variant in the NF1 gene. The most characteristic feature of the condition NF1 is the neurofibroma, a benign, multi-cellular tumor which initiates when a cell of the Schwann cell lineage gains a somatic pathogenic variant of the other NF1 allele. Neurofibromas developing at nerve termini in the skin are termed “cutaneous” neurofibromas (cNFs), while those developing within larger nerves are termed “plexiform.” Most patients develop cNFs beginning in late childhood or early adulthood, continuing throughout life at variable rates. Some patients may develop only a few cNFs, while others suffer from thousands. There are no reliably effective physical or pharmaceutical therapies besides surgical removal. Although these are not life-threatening, they are disfiguring and can interfere with normal life functions. To provide a resource for research, we developed short-term cNF Schwann cell cultures from NF1 patients, from which we subsequently established the first semi-immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase ( hTERT ) and murine cyclin-dependent kinase 4 ( mCdk4 ) genes. Here we present molecular, cellular, and functional characterization of these cell lines, which will be of utility for investigating and developing NF1 cNF therapies.

Year:

2025

With the increasing use of comprehensive germline genetic testing of children and adolescents with cancer, it has become evident that pathogenic variants (PV) in adult-onset cancer predisposition genes (aoCPG) underlying adult-onset cancer predisposition syndromes, such as Lynch syndrome or hereditary breast and ovarian cancer, are enriched and reported in 1% to 2% of children and adolescents with cancer. However, the causal relationship between PVs in aoCPGs and childhood cancer is still under investigation. The best-studied examples include heterozygous PVs in mismatch repair genes associated with Lynch syndrome in children with mismatch repair deficient high-grade glioma, heterozygous PVs in BARD1 in childhood neuroblastoma, and heterozygous PVs in BRCA2 in children with rhabdomyosarcoma. The low penetrance for pediatric cancers is considered to result from a combination of the low baseline risk of cancer in childhood and the report of only a modest relative risk of disease in childhood. Therefore, we do not advise that healthy children empirically be tested for PVs in an aoCPG before adulthood outside a research study. However, germline panel testing is increasingly being performed in children and adolescents with cancer, and exome and genome sequencing may be offered more commonly in this population in the future. The precise pediatric cancer risks and spectra associated with PVs in aoCPGs, underlying cellular mechanisms and somatic mutational signatures, as well as treatment response, second neoplasm risks, and psycho-oncological aspects require further research.

Year:

2024

Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. Previously, a germline pathogenic variant (GPV) in PHOX2B was associated with Hirschsprung disease and congenital central hypoventilation syndrome. Recently, certain GPVs were shown to be responsible for congenital central hypoventilation syndrome and NB predisposition. Also, several groups determined that activating GPVs in ALK accounted for a substantial number of familial NB. Finally, there are additional genes and cancer predisposition syndromes in which NB occurs with greater frequency or that have been associated with NB based on genome-wide association studies. We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Collaborators (49)

Amanda Janitz

Assistant Professor in Epidemiology

-

UNITED STATES
View details

Sharon E. Plon

Professor and Assistant Dean

Baylor College of Medicine

UNITED STATES
View details

Smita Bhatia

Professor

The University of Alabama

UNITED STATES
View details

Eric J. Chow

Seattle Children's Hospital

UNITED STATES
View details

Sharon Diskin

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Lisa J. McReynolds

National Institutes of Health

UNITED STATES
View details

Dominik T. Schneider

Witten/Herdecke University

GERMANY
View details

Garrett Brodeur

Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Sang Lee

Johns Hopkins University School of Medicine

UNITED STATES
View details

Dominique Stoppa-Lyonnet

Institut Curie

FRANCE
View details

Joseph Neglia

Professor

University of Minnesota Medical School Twin Cities

UNITED STATES
View details

Megan Frone

National Institutes of Health

UNITED STATES
View details

Kuan-lin Huang

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Kenji Kamiya

Hiroshima University

JAPAN
View details

William Foulkes

Full Professor

McGill University

CANADA
View details

Jeremy M. Schraw

Voluntary Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Frank Lin

Baylor College of Medicine Department of Pediatrics

UNITED STATES
View details

Louis P. Dehner

-

UNITED STATES
View details

Eduard Serra

Researcher

Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

SPAIN
View details

Gregory Armstrong

Endowed Chair in Epidemiology and Cancer Control

St. Jude Children's Research Hospital

UNITED STATES
View details

Andrew Bauer

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Kara Maxwell

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

David Wilson

Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Nathalie Japkowicz

American University

UNITED STATES
View details

Philip Lupo

Professor

Emory University

UNITED STATES
View details

Yutaka Yasui

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Jaishri Blakeley

Johns Hopkins University

UNITED STATES
View details

Kenneth S. Chen

University of Texas Southwestern Medical Center

UNITED STATES
View details

Jo Lynne Rokita

Director, Brain Tumor Institute Bioinformatics Core

Children's National Health System

UNITED STATES
View details

David Watson

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Margaret Wallace

Professor

University of Florida College of Medicine

UNITED STATES
View details

Lindsay Frazier

Professor and Institute Physician

Dana-Farber Cancer Institute

UNITED STATES
View details

Arikuni Uchimura

Laboratory Chief

-

JAPAN
View details

Angela C. Hirbe

Washington University School of Medicine

UNITED STATES
View details

Giselle L. Saulnier Sholler

-

UNITED STATES
View details

Meritxell Carrio

Associate researcher

Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

SPAIN
View details

Michael Sargen

Lasker Clinical Research Scholar

National Cancer Institute

UNITED STATES
View details

Sarah Scollon

Assistant Professsor/Genetic Counselor

Baylor College of Medicine

UNITED STATES
View details

Piyushkumar Mundra

Children's Cancer Institute Australia

AUSTRALIA
View details

Deeann Wallis

The University of Alabama

UNITED STATES
View details

Donald Parsons

Professor

Baylor College of Medicine

UNITED STATES
View details

Philip Rosenberg

Principal Investigator

National Cancer Institute

UNITED STATES
View details

Sogol Mostoufi-Moab

Associate Professor of Pediatrics

Children's Hospital of Philadelphia

UNITED STATES
View details

Lucie M. Turcotte

University of Minnesota

UNITED STATES
View details

Joshua Schiffman

Professor

University of Utah Health

UNITED STATES
View details

Martin Zenker

Full professor, head of department

University Hospital Magdeburg

GERMANY
View details

Allison Pribnow

Clinical Assistant Professor

Stanford University

UNITED STATES
View details

Zois Boukouvalas

Assistant Professor

American University

UNITED STATES
View details

Anita Ng

Feinstein Institute for Medical Research

UNITED STATES
View details